Diagnostic accuracy of [
Biochemical recurrence
PET/CT
PSMA
Positron emission tomography
Prostate cancer
Prostate-specific membrane antigen
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
29
08
2021
accepted:
13
01
2022
pubmed:
25
1
2022
medline:
26
5
2022
entrez:
24
1
2022
Statut:
ppublish
Résumé
Despite increasing use for the detection of biochemically recurrent prostate cancer (rPC), the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT) with [ One hundred seventy-seven consecutive patients undergoing [ The overall PET-positivity rate was 91%. Conclusive follow-up for affirmation or refutation of a PSMA-positive lesion was available for 81/152 patients on a per region basis. In this subgroup, overall sensitivity, specificity, PPV, and NPV were 95% (CI: 0.90-0.98), 89% (CI: 0.83-0.93), 86% (0.80-0.90), and 96% (CI: 0.92-0.98), respectively. On a per region basis, PPV was 97% (CI: 0.83-0.99) for local recurrence, 93% (CI: 0.78-0.98) for pelvic LN, 87% (CI: 0.62-0.96) for retroperitoneal LN, 82% (CI: 0.52-0.95) for supradiaphragmatic LN, and 79% (0.65-0.89) for bone lesions. The number of solid organ metastases (n = 6) was too small for an accurate statistical analysis. The known high PET-positivity rate of [
Identifiants
pubmed: 35067735
doi: 10.1007/s00259-022-05693-0
pii: 10.1007/s00259-022-05693-0
pmc: PMC9165245
doi:
Substances chimiques
Gallium Radioisotopes
0
Oligopeptides
0
PSMA-1007
0
Niacinamide
25X51I8RD4
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2436-2444Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2020 May;61(5):702-709
pubmed: 31836686
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494
pubmed: 34120201
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Lancet Oncol. 2019 Sep;20(9):1193-1195
pubmed: 31375470
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
EJNMMI Res. 2021 Apr 30;11(1):41
pubmed: 33929626
EJNMMI Res. 2019 Jul 25;9(1):66
pubmed: 31346821
Clin Nucl Med. 2019 Jun;44(6):e401-e403
pubmed: 30932984
Ann Nucl Med. 2021 Apr;35(4):523-528
pubmed: 33661475
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):642-651
pubmed: 31865408
Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4252-4261
pubmed: 34773473
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):614-623
pubmed: 31792572
J Nucl Med. 2020 May;61(5):729-734
pubmed: 31628219
Clin Nucl Med. 2019 Dec;44(12):e629-e633
pubmed: 31689286
Nucl Med Commun. 2019 Oct;40(10):975-979
pubmed: 31365499
J Nucl Med. 2021 Feb;62(2):208-213
pubmed: 32817141
J Nucl Med. 2015 Nov;56(11):1697-705
pubmed: 26294298
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126071
J Urol. 2019 Sep;202(3):533-538
pubmed: 31042111
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4495-4507
pubmed: 34136957
J Nucl Med. 2021 Sep 1;62(9):1252-1257
pubmed: 33547214
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Nucl Med Commun. 2019 Jun;40(6):652-656
pubmed: 30855543
Lancet Oncol. 2019 Nov;20(11):e608
pubmed: 31674313
J Nucl Med. 2021 Nov;62(11):1550-1557
pubmed: 33712533
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
pubmed: 22042970
J Nucl Med. 2020 Jan;61(1):51-57
pubmed: 31253741
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):343-348
pubmed: 31780781
Nucl Med Commun. 2021 May 1;42(5):495-502
pubmed: 33481506
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):160-167
pubmed: 31628514
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2978-2989
pubmed: 33550425